Whilst working on a recent European application for an Orphan Drug Designation (ODD) for a rare neurological condition that was being made to the EMA, …
Revised Response Evaluation Criteria in Solid Tumours (RECIST 1.1) came into effect in 2009 in order to address the issues and limitations of RECIST 1.0. …
It is a GMP requirement to certify the vendor to deliver high quality and safe medicines, and to prevent recalls, deaths, adverse events, and serious …
Nowhere is the advance of technology felt more acutely than in the field of healthcare and clinical research. The very future of the industry relies …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
